BACKGROUND: Elevated circulating levels of fetuin-A in blood have been associated with increased risk of cardiovascular disease. The goal of our study was to prospectively investigate the potential causal nature of the association between fetuin-A levels and myocardial infarction (MI) and ischemic stroke by applying a Mendelian randomization approach. METHODS AND RESULTS: Five tagging single-nucleotide polymorphisms (rs2248690, rs2070633, rs2070635, rs4917, and rs6787344) capturing the common genetic variation of the fetuin-A coding gene alpha(2)-Heremans-Schmid glycoprotein (AHSG) were genotyped in a case-cohort comprising 214 MI cases, 154 ischemic stroke cases, and 2152 persons who remained free of cardiovascular disease events in the European Prospective Investigation into Cancer and Nutrition-Potsdam study. One single-nucleotide polymorphism (rs6787344) was discarded because of Hardy-Weinberg disequilibrium. All AHSG tagging single-nucleotide polymorphisms were associated with fetuin-A plasma levels (P<0.0001). AHSG rs4917 C>T showed the strongest association, explaining 21.2% of the phenotypic variance independent of potential confounding factors (+35.5 microg/mL increase per C-allele, P= 2 x 10(-121)). Furthermore, the rs4917 C-allele showed a significant association with MI (adjusted hazard rate ratio [RR] 1.34, 95% CI 1.05 to 1.70, P=0.02). Based on this association, the expected RR for MI corresponding to 1 SD in fetuin-A was 1.54 and, thus, strikingly matches the previously observed association between fetuin-A plasma levels and MI risk (RR 1.59). CONCLUSIONS: These data provide evidence for the causal nature of the recently reported association between fetuin-A plasma levels and MI risk, thereby suggesting an involvement of fetuin-A in the pathogenesis of cardiovascular disease.
BACKGROUND: Elevated circulating levels of fetuin-A in blood have been associated with increased risk of cardiovascular disease. The goal of our study was to prospectively investigate the potential causal nature of the association between fetuin-A levels and myocardial infarction (MI) and ischemic stroke by applying a Mendelian randomization approach. METHODS AND RESULTS: Five tagging single-nucleotide polymorphisms (rs2248690, rs2070633, rs2070635, rs4917, and rs6787344) capturing the common genetic variation of the fetuin-A coding gene alpha(2)-Heremans-Schmid glycoprotein (AHSG) were genotyped in a case-cohort comprising 214 MI cases, 154 ischemic stroke cases, and 2152 persons who remained free of cardiovascular disease events in the European Prospective Investigation into Cancer and Nutrition-Potsdam study. One single-nucleotide polymorphism (rs6787344) was discarded because of Hardy-Weinberg disequilibrium. All AHSG tagging single-nucleotide polymorphisms were associated with fetuin-A plasma levels (P<0.0001). AHSGrs4917 C>T showed the strongest association, explaining 21.2% of the phenotypic variance independent of potential confounding factors (+35.5 microg/mL increase per C-allele, P= 2 x 10(-121)). Furthermore, the rs4917 C-allele showed a significant association with MI (adjusted hazard rate ratio [RR] 1.34, 95% CI 1.05 to 1.70, P=0.02). Based on this association, the expected RR for MI corresponding to 1 SD in fetuin-A was 1.54 and, thus, strikingly matches the previously observed association between fetuin-A plasma levels and MI risk (RR 1.59). CONCLUSIONS: These data provide evidence for the causal nature of the recently reported association between fetuin-A plasma levels and MI risk, thereby suggesting an involvement of fetuin-A in the pathogenesis of cardiovascular disease.
Authors: Janine Kröger; Karina Meidtner; Norbert Stefan; Marcela Guevara; Nicola D Kerrison; Eva Ardanaz; Dagfinn Aune; Heiner Boeing; Miren Dorronsoro; Courtney Dow; Guy Fagherazzi; Paul W Franks; Heinz Freisling; Marc J Gunter; José María Huerta; Rudolf Kaaks; Timothy J Key; Kay Tee Khaw; Vittorio Krogh; Tilman Kühn; Francesca Romana Mancini; Amalia Mattiello; Peter M Nilsson; Anja Olsen; Kim Overvad; Domenico Palli; J Ramón Quirós; Olov Rolandsson; Carlotta Sacerdote; Núria Sala; Elena Salamanca-Fernández; Ivonne Sluijs; Annemieke M W Spijkerman; Anne Tjonneland; Konstantinos K Tsilidis; Rosario Tumino; Yvonne T van der Schouw; Nita G Forouhi; Stephen J Sharp; Claudia Langenberg; Elio Riboli; Matthias B Schulze; Nicholas J Wareham Journal: Diabetes Date: 2018-03-09 Impact factor: 9.461
Authors: C Sritara; A Thakkinstian; B Ongphiphadhanakul; L Chailurkit; S Chanprasertyothin; W Ratanachaiwong; P Vathesatogkit; P Sritara Journal: Osteoporos Int Date: 2014-02-26 Impact factor: 4.507
Authors: Xiaowen Liu; Ole-Petter R Hamnvik; John P Chamberland; Michael Petrou; Huizhi Gong; Costas A Christophi; David C Christiani; Stefanos N Kales; Christos S Mantzoros Journal: Metabolism Date: 2014-03-15 Impact factor: 8.694
Authors: Sarah A Aroner; David E St-Jules; Kenneth J Mukamal; Ronit Katz; Michael G Shlipak; Michael H Criqui; Bryan Kestenbaum; David S Siscovick; Ian H de Boer; Nancy S Jenny; Matthew J Budoff; Joachim H Ix; Majken K Jensen Journal: Atherosclerosis Date: 2016-03-22 Impact factor: 5.162